Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...100101102103104105106107108109110...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Clinical, P2 data, Journal, PD(L)-1 Biomarker, IO Biomarker:  Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. (Pubmed Central) -  Jun 18, 2020   
    P1b/2
    Lenvatinib plus pembrolizumab showed anti-tumour activity in patients with advanced recurrent endometrial cancer with a safety profile that was similar to those previously reported for lenvatinib and pembrolizumab monotherapies, apart from an increased frequency of hypothyroidism. Lenvatinib plus pembrolizumab could represent a new potential treatment option for this patient population, and is being investigated in a randomised phase 3 study.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion:  HOPE: Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (clinicaltrials.gov) -  Jun 17, 2020   
    P2,  N=39, Completed, 
    Lenvatinib plus pembrolizumab could represent a new potential treatment option for this patient population, and is being investigated in a randomised phase 3 study. Active, not recruiting --> Completed
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  The Underlying Mechanisms of Noncoding RNAs in the Chemoresistance of Hepatocellular Carcinoma. (Pubmed Central) -  Jun 9, 2020   
    A deeper understanding of the molecular mechanisms responsible for ncRNA-mediated drug resistance in HCC will provide new opportunities for improving the treatment of HCC. In this review, we summarize recent findings on the molecular mechanisms by which ncRNAs regulate HCC chemoresistance, as well as their potential clinical implications in overcoming HCC chemoresistance.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma. (Pubmed Central) -  Jun 9, 2020   
    However, sorafenib, as the first approved systemic treatment in 2007, only increased overall survival by three months in advanced HCC patients...Lenvatinib acts as a first-line drug, whereas regorafenib, ramucirumab, and cabozantinib are defined as second-line drugs...Combined immunotherapies with matched molecular targeted treatments would be a novel breakthrough. Herein, we summarize the current statuses of immunotherapies and molecular targeted drug therapies, and mainly identify clinically feasible chemoimmunotherapeutic strategies.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Metastases:  Lenvatinib and Pembrolizumab in People with Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers (clinicaltrials.gov) -  Jun 4, 2020   
    P2,  N=64, Recruiting, 
    Herein, we summarize the current statuses of immunotherapies and molecular targeted drug therapies, and mainly identify clinically feasible chemoimmunotherapeutic strategies. Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma (clinicaltrials.gov) -  Jun 2, 2020   
    P2,  N=33, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2020 --> May 2021
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment change, Trial withdrawal:  Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) -  May 21, 2020   
    P2,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=25 --> 0 | Suspended --> Withdrawn
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. (Pubmed Central) -  May 20, 2020   
    Several criteria can be used to assess response to treatment, such as quantitative perfusion on cross-sectional imaging and novel/emerging MRI techniques, including a host of known and emerging biomarkers and radiogenomics. This review addresses the pathophysiology of angiogenesis in HCC, accurate imaging assessment of angiogenesis, monitoring effects of anti-angiogenic therapy to guide future treatment and assessing prognosis.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    ? Lenvatinib 2nd line (Twitter) -  May 17, 2020